The 5 analysts offering 12-month price forecasts for Erytech Pharma SA have a median target of 21.95, with a high estimate of 28.93 and a low estimate of 13.00. The median estimate represents a +188.76% increase from the last price of 7.60.
The current consensus among 5 polled investment analysts is to Buy stock in Erytech Pharma SA. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share --
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.